Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  


Foundation Fighting Blindness and Harrington Discovery Institute

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.

• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.

For more information about Foundation Fighting Blindness visit the Fighting Blindness website.

 
The Ohio Clinical Trial Collaborative (OCTC)

The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.

The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.

Review the OCTC working website at: http://ohioclintrials.org.

Contact Joe Peter at 216-702-5314 for more information.

 
Division of Infectious Diseases & HIV Medicine, CWRU and UH Case Medical Center

Announcement of Infectious Diseases Research Support from STERIS Corporation
The Division of Infectious Diseases & HIV Medicine at Case Western Reserve University and University Hospitals Case Medical Center, with funds from STERIS Corporation, will provide seed money to faculty to foster research in emerging and healthcare-associated infections.

Announcement of Infectious Diseases Research Support from the Infectious Diseases & Immunology Institute (IDII)
The Infectious Diseases & Immunology Institute (IDII) at Case Western Reserve University will provide seed money to young investigators (within 5 years of appointment) to foster interdisciplinary research in infectious diseases and immunology.

For more information on these opportunities, please contact Martha Salata at 844-1988 or mks18@case.edu or visit the Center’s website.

 
Guidance for Transferring Research Materials and Data

All data and materials transferred into and outside of the institution require either a Material Transfer Agreement (MTA), a Data Use Agreement (DUA), or both. Material Transfer Agreements are used for the transfer of tangible materials (cell lines, mice, metallurgical samples, biological specimens), whereas Data Use Agreements are used for electronic or hardcopy data (including Protected Health Information, de-identified patient data, and non-human data).

All MTAs and DUAs should be routed through the Technology Transfer Office by sending a request to Andrew Jarrell at andrew.jarrell@case.edu.

 
National Multiple Sclerosis Society

The Barancik Prize for Innovation in Multiple Sclerosis Research recognizes an exceptional scientist or a team of scientists whose work in MS research has demonstrated outstanding innovation and originality.

The prize is administered by the National Multiple Sclerosis Society. A selection committee comprised of leaders in science, medicine, and MS advocacy will review nominees. The committee will evaluate:
• Exceptional innovation and originality in scientific research relevant to MS
• Impact and potential of the research to lead to pathways for the treatment and cure for MS
• Scientific accomplishments that merit recognition as a future leader in MS research

For more information and guidelines , visit the Society’s website.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.